SMCs
In culture conditions, vascular SMCs are robust, do not have stringent growth requirements, and are transduced relatively easily. Hence, these cells are ideal for cell-based vascular gene transfer. Potential applications include modulating local vascular phenomena and obtaining systemic gene delivery. 3 Feasibility of cell-based vascular gene transfer was demonstrated first by Plautz and coworkers. 4 SMCs transduced in vitro with recombinant ␤-galactosidase were infused into denuded porcine iliofemoral arteries with use of a doubleballoon catheter. Transgene expression in the arterial segments could be demonstrated up to 11 days after infusion. Recently, such an approach was used to obtain biological effects. Overexpression of a tissue inhibitor of matrix metalloproteinase (TIMP)-1 was achieved by seeding SMCs transduced with the TIMP-1 vector into injured carotid arteries of rats. This resulted in a significant decrease in neointimal hyperplasia in comparison with arteries seeded with controlvector-transduced cells. 5 In the same model, cell-based overexpression of endothelial nitric oxide synthase (eNOS) resulted in vascular remodeling and luminal enlargement. 6 Genetically engineered SMCs seeded in a vascular graft may be used for long-term local and systemic gene therapy. 7 Although SMCs could be used as a biological lining for endovascular stents, bypass grafts, and left ventricular assist devices, such a lining may be thrombogenic. Gene transfer of eNOS or cyclooxygenase-l to SMCs is a possible solution to this problem. Indeed, expression of recombinant eNOS in coronary artery SMCs increases NOS enzymatic activity and cyclic 3Ј-5Ј-guanosine monophosphate (cGMP) levels and nitrite production. 8 These findings are similar to those of Scott-Burden and coworkers, 9 although in their study nitric oxide (NO) production by recombinant eNOS occurred only in the presence of tetrahydrobiopterin, a cofactor for eNOS. Therefore, phenotypic changes that occur with subculturing ex vivo may affect the results of cell-based gene transfer. For example, in eNOS gene transfer, changes in tetrahydrobiopterin availability and guanylate cyclase activity may determine functionality of the transgene. Thus, even after successful gene transfer, eventual effects may be influenced by the nature of the target cell and biology of the recombinant protein ( Figure) .
The potential of SMC-based gene transfer as a means of systemic gene delivery has been demonstrated in a study in which rat arteries were seeded with SMCs transduced with a retroviral vector encoding a cDNA for erythropoietin. 10 An increase in red blood cell mass was noted for up to 11 weeks. Other potential methods of systemic delivery using genetically engineered SMCs include embolization into a microvascular bed 11 and incorporation into a synthetic structure supplied by an induced neovasculature. 12 
ECs
The feasibility of using ECs for cell-based vascular wall gene therapy was demonstrated in a study in which genetically modified ECs were transplanted successfully into the arterial wall of a pig. 13 Another study demonstrated transgene expression in Dacron grafts seeded with autologous genetically modified ECs and implanted as carotid interposition grafts in dogs. 14 Dichek 's group 15 used the cell-based approach to modify vascular stents. Sheep ECs expressing human tissue plasminogen activator were seeded onto balloon-expandable stents in vitro. Complete coverage of stent surfaces was achieved after several days in culture, and such stents could be deployed in a pulsatile flow system with significant retention and survival of the seeded ECs. 16 Furthermore, implantation of ECs expressing tissue plasminogen activator into vascular grafts decreased platelet and fibrin formation in a baboon model of arteriovenous shunt thrombosis. 17 Cell-based gene transfer using ECs is a potential means of systemic gene delivery. Genetically modified ECs can become incorporated into the endothelium of a microvascular capillary network. 11 The capillary bed of skeletal muscle, for example, could serve as a recipient site for transduced, autologous ECs for systemic gene delivery. 11 A notable recent advance is the discovery that putative EC progenitors, or angioblasts, are present in human peripheral blood. 18 These cells can be separated on the basis of cell surface antigen expression, and they differentiate into ECs in vitro. In animal models of ischemia, these cells home onto foci of angiogenesis. 18 Potentially, such cells could be used as autologous vectors for vascular gene transfer. Angiogenesis at sites of myocardial or skeletal ischemia could be enhanced by transfecting EC progenitors with angiogenic transgenes and introducing them into the circulation.
Ex Vivo Gene Transfer to the Vessel Wall
Ex vivo gene transfer is particularly suited for the genetic modification of venous or arterial bypass grafts. Such grafts can be genetically engineered ex vivo with optimized transfection efficiency and minimization of toxicity. The harvested vein or artery intended for use as a bypass graft can be transduced ex vivo by placing it in a vector solution before implantation. Liposomes as well as viral vectors can be used for transducing vessel segments. Transgene expression generally is noted in the adventitia and the endothelium but not in the media. 19 The technique is relatively simple and safe, and bypass grafts genetically engineered ex vivo currently are undergoing testing in clinical trials. 20 
In Vivo Gene Transfer to the Vascular Wall
In vivo vascular gene transfer was performed first in porcine iliofemoral arteries with use of a double-balloon catheter and retroviral and plasmid vectors encoding ␤-galactosidase. 21 Expression of ␤-galactosidase could be demonstrated for up to 3 months after gene transfer. Since this landmark study,
TABLE 1. Unique Features of Vasculature as Target Organ for Gene Transfer
The endothelium offers a large surface area and easy accessibility for gene transfer
The architecture of the normal vessel wall is relatively simple: 3 layers (endothelium, media, and adventitia) and 3 main cell types (endothelial cells, smooth muscle cells, and fibroblasts) Gene transfer can be targeted to a specific site or to the entire vasculature Transgene products may be secreted locally to achieve an autocrine-paracrine effect or into the bloodstream for a systemic effect
The elastic laminae act as barriers to vectors; thus, transfer and expression of genetic material can be localized to a specific layer
The branching nature of the vasculature is an anatomical factor likely to affect site specificity of gene transfer
In an atherosclerotic vessel wall, calcification, neovascularization, presence of a cellular infiltrate, and a lipid core are likely to affect the location and efficiency of gene transfer 23 Up to 35% of ECs are transduced by this method. 23 So far, few studies have considered the expression of therapeutically relevant genes in the endothelium in vivo. In a recent study, endothelium-specific expression of recombinant eNOS resulted in altered vascular reactivity. 24 Significantly higher cGMP levels were present in eNOS-transduced arteries, and contractile responses to phenylephrine were diminished. Additionally, endotheliumdependent relaxations to acetylcholine were enhanced significantly in the eNOS-transduced arteries.
Gene Transfer to the Media
SMCs are the principal cellular component of arteries and veins and have a key role in various vascular diseases, including atherosclerosis, restenosis, vein graft disease, and transplant vasculopathy. 25 SMC migration, proliferation, and matrix secretion are important factors in the development of neointimal proliferation. 25 Therefore, SMCs are an important target of various systemic and local therapies to limit neointimal formation. Luminal gene delivery may result in medial SMC transduction if the vector solution is injected at high pressure or the elastic lamina is disrupted by balloon angioplasty. Several investigators have demonstrated decreased neointimal formation by expression of various transgenes in the media after arterial injury.
Gene Transfer to the Adventitia
Adventitial gene transfer avoids interruption of blood flow, disruption of the endothelium, and systemic distribution of the vector. 26 Recently, the adventitia has been shown to participate in remodeling and neointimal formation after arterial injury. [27] [28] [29] The adventitia also may influence atherogenesis 30 and vascular hypertrophy secondary to hypertension. 31 Therefore, the adventitia is a target for site-specific vascular wall therapy. Adventitial-specific gene transfer after delivery of adenoviral vectors into the periarterial sheath has been demonstrated in different animal models. 26, 32 Adventitial delivery of vectors for gene transfer may be achieved easily in large peripheral arteries by direct application during surgery and in cerebral arteries by instillation into the cerebrospinal fluid. 33 Adventitial delivery to the coronary arteries may be possible with novel strategies such as delivery of vectors to the pericardial space 34 or by percutaneous intervention using special catheters. 35 Gene transfer to the adventitia of pulmonary arteries is achieved by aerosolization of adenoviral vectors. 36 Expression of recombinant eNOS in the adventitia of the carotid arteries of rabbits leads to a marked increase in NOS enzymatic activity and an alteration in vascular reactivity. 32 Delivery of the eNOS vector to the cerebrospinal fluid in a dog model led to expression of the transgene in the adventitia of cerebral vessels and enhanced relaxations of the vessels to bradykinin. 37 
Vectors for Vascular Gene Transfer
Ideally, a vector for gene transfer should be easily produced, available in a concentrated form, tissue-specific, nontoxic, and nonimmunogenic, provide long-term expression, and allow a broad range of transgene size. Such a vector currently does not exist. A detailed description of the vectors available for vascular gene transfer is outside the scope of this review. The advantages and disadvantages of the commonly used vectors for vascular gene transfer are listed in Table 3 . Technical improvement in vectors may permit more efficient and cell-specific gene transfer, avoid immune-inflammatory responses, and maintain gene expression for long periods. These improvements would be a major step toward realizing the potential of gene therapy for vascular diseases. Newer vectors for gene transfer include the adeno-associated virus (AAV) and lentivirus. Like adenoviral vectors, AAV vectors are able to transduce many different cell types and do not need active cell proliferation for transduction. Additionally, these vectors may be less immunogenic and may obtain a more prolonged transgene expression. 41 The usefulness of AAV vectors in vascular gene delivery has been demonstrated in cultured SMCs and ECs from various species as well as in vivo delivery to the arterial wall. 42 Lentiviral vectors are able to infect nondividing cells, overcoming a major drawback of retroviral vectors. 43 Concern about the safety of such vectors led to attempts to develop multiplyattenuated lentiviral vectors. 44 Vectors based on nonprimate lentiviruses such as feline immunodeficiency virus are also being evaluated. 45 The major shortcomings of available vectors and ways to improve these are discussed below.
Vectors Elicit Inflammation
Viral vectors have the potential to induce an inflammatoryimmune response, 46 leading to tissue damage, and a decrease in the duration of transgene expression, particularly in case of adenoviral vectors. Adenoviral vectors, from which all transcriptional coding regions have been deleted ('backbone' vectors), have been developed to minimize inflammatory or immune responses. 47 Immune response to viral vectors could be inhibited by administering immunosuppressant drugs 48 or cotransfection of vectors expressing immunomodulatory genes. 49 
Expression of Transgenes May Be Transient
Long-term expression of transgenes may be desirable in certain situations. This requires chromosomal integration with retroviral vectors or the stable episomal presence of an adenoviral vector without the loss of transgene promoter activity. In tissues with high cell turnover, the expression of transgene after adenoviral-mediated gene transfer may be shortened by loss of the episomal, nonreplicating vector genome. In addition, clearance of transduced cells by the host immune system also limits duration of transgene expression. A decrease in the activity of the promoter in vivo ("promoter attenuation") due to incompletely understood mechanisms is also responsible for decreased transgene expression with time. 50 Increased duration of expression may result from improved vector design or by modulation of the host defense system, as discussed above.
Vectors Lack Cell or Tissue Specificity
Targeted gene delivery can be accomplished by using either cell-specific promoters or constructing vectors with defined cell tropism. Tissue-specific expression can be achieved by using a tissue-or cell-specific promoter to drive the transgene. Examples of endothelial-specific promoters include thrombomodulin, 51 von Willebrand factor, 52 and tie-2. The latter is an endothelial-specific receptor tyrosine kinase essential for the regulation of vasculogenesis and remodeling. 53 Use of the tie-2 promoter resulted in reporter gene expression in vascular ECs throughout embryogenesis and adulthood in mice. 54 An arterial SMC-specific promoter, SM22 alpha, that activates transcription exclusively in arterial SMCs has been used to restrict expression of a recombinant adenoviral vector to SMCs. 55 Vectors with a defined cell tropism may be constructed by several different strategies. For viral vectors, one approach for altering tropism is to modify surface proteins that interact with cell surface receptors. This has been demonstrated for retroviral vectors. 56 In adenoviral vectors, tissue specificity may be altered by modifying either the fiber or penton capsid proteins that mediate interaction with cell surface receptors. 57, 58 Plasmid DNA can be tissue-targeted with receptormediated gene delivery. After a unique receptor protein in the tissue of interest has been identified, a natural ligand or an antibody to the receptor can be conjugated to polylysine or some other coupling agent to deliver DNA. 59 Transgene Expression Is Unregulated Most vascular gene transfer approaches have used viral promoters to drive constitutive gene expression. However, vascular gene therapy may require regulating gene expression over time to titrate therapeutic effects. The use of inducible promoters would allow the administration of exogenous agents that could drive transgene expression. Several types of regulatable vectors have been developed. An example is a system based on the Escherichia coli tetracycline-responsive promoter (tet). 60 A 'gene switch' is thereby constructed that allows the transgene to be specifically turned on/off in response to tetracycline.
An intriguing concept is the regulation of transgene expression by endogenous stimuli such as inflammation and hypoxia. Placing a transgene under the control of a cytokineinducible promoter may allow production of the recombinant protein only in the setting of an inflammatory response. The intensity and duration of the inflammatory response would then drive transgene expression. 61 Similarly, hypoxia, a potent modulator of gene expression, 62, 63 could be used for regulating transgene expression. Modulation caused by hypoxia results from the interaction of a transcriptional complex called "hypoxia-inducible factor-1" (HIF-1), with its DNA recognition site, the hypoxia response element (HRE). 64, 65 This HIF-1-HRE-dependent system of inducible gene expression is present in all mammalian cells that have been tested 66 and may be useful in directing gene expression in ischemic myocardium or skeletal muscle. 63 
Delivery of Vectors to the Vasculature
Delivery of vectors for gene transfer into specific arterial beds poses significant technical challenges unique to each anatomical site. Ideally, a system to deliver vectors to a vascular bed should be catheter based, permit distal perfusion of the target organ while the vector is being delivered, and allow subsequent retrieval of the vector to avoid the potential dangers of systemic dissemination. Vector delivery may have to be made to an entire arterial bed (to ameliorate conditions like atherosclerosis and transplant vasculopathy) or it may be sitespecific (to modulate localized arterial lesions). Transduction of an entire vascular bed would require advanced catheter techniques or it could be achieved at the time of arterial bypass surgery or organ transplantation. 67 For site-specific gene delivery, the branching nature of the arterial bed and the potential for ischemic damage from prolonged balloon inflation pose significant challenges. In both situations, unknown transfection efficiency with advanced atheromatous disease and the possibility of systemic dissemination of the vector need to be considered. Initially, in vivo gene transfer to the vasculature involved infusion of the vector into a segment of an artery isolated by sealing it at 2 locations with a double-balloon catheter. 21 Next, efforts were made to develop perfusion catheters that permitted blood flow through an artery while delivering vectors. Such catheters included a modification of the doubleballoon catheter, 68 the channel balloon (which has an array of channels with pores surrounding an inner balloon), 69 and the Dispatch catheter (which isolates a segment of an artery, using a thin polymer membrane on a spiral balloon). 70 Another method of gene delivery takes advantage of the hydrophilic polymer (hydrogel) coating present on some angioplasty catheters. A vector solution contained in the polymer is delivered to the vessel wall with balloon inflation. 71 Recently, a "needle injection" catheter has been developed that allows direct gene transfer to the adventitia or the media. 35 This is achieved by multiple small needles, which are arranged linearly along the surface of the balloon, that penetrate the vessel wall as the balloon is inflated. Finally, stents need to be considered as potential vehicles for gene transfer because of their increasing use in vascular interventions. The feasibility of coating stents with genetically engineered ECs has been demonstrated. 15, 16 A biopolymer coating such as fibrin polymer can be used to cover the metal scaffolding of a stent and as a vehicle to deliver transduced cells or vectors to the vessel wall. 72 Similarly, stents made entirely of a bioresorbable polymer may prove to be useful adjunctive devices for vascular gene transfer. 73 Successful gene transfer and expression have been demonstrated after implantation of polymeric stents impregnated with an adenoviral vector encoding ␤-galactosidase in rabbit carotid arteries. 74 
Part II: Therapeutic Potential
Part II is an overview of the potential use of gene transfer in the treatment of vascular diseases, including atherosclerosis, arterial restenosis, vein graft disease, systemic and pulmonary hypertension, and cerebrovascular disease. Most of the discussion is based on studies performed in animal arteries that do not have the same lesions as diseased arteries of humans. At best, these studies are "proof-of-principle" studies, setting the stage for further testing in models more representative of human disease or in humans themselves.
Atherosclerotic Vascular Disease
Atherosclerosis is a complex disorder. Vascular gene transfer strategies for atherosclerosis may be directed at atherogenesis itself or at the important sequelae of atherosclerosis, such as thrombosis and ischemia.
Antiatherogenic Strategies
Early atherogenesis is characterized by endothelial dysfunction that manifests as impaired endothelium-dependent relaxations and increased adhesiveness to circulating white blood cells. Decreased bioavailability of NO, from either decreased production or due to scavenging by free oxygen radicals, seems to be a key factor in endothelial dysfunction. 75 NO has several antiatherogenic properties. 76 In addition to its role as an endogenous vasodilator, it inhibits SMC growth and migration, nuclear factor kappa B (NF-B) activity, 77 and the expression of proinflammatory molecules such as vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. 78, 79 Endothelial function may be enhanced and atherogenesis retarded by increasing local NO production through overexpression of eNOS. 24 However, increased NO production may not necessarily be beneficial in advanced atherosclerosis. 80 Indeed, there is potential for increased production of damaging free radicals such as superoxide and peroxynitrite, with resulting vascular damage. 81, 82 Coexpression of transgenes that encode for antioxidant proteins might be useful in such a setting. 83, 84 Other antiatherogenic proteins that are candidates for gene therapy for atherosclerosis include apo A-I, the principal apolipoprotein of high-density lipoprotein, which promotes reverse cholesterol transport in atherosclerotic lesions, 85, 86 and apo E, the ligand involved in clearance of lipoprotein particles from the circulation. 87, 88 Thrombosis Most acute ischemic syndromes result from thrombosis subsequent to rupture of an atheromatous plaque. Thrombin, a central molecule in blood coagulation, may be inhibited by expression of recombinant hirudin. 89 Other antithrombotic approaches include overexpression of cyclooxygenase to augment prostacyclin synthesis 90 and overexpression of tissue plasminogen activator to enhance fibrinolysis. 91 The delay between administration of vector and the onset of antithrombotic effects means that such a strategy is unlikely to be effective in acute settings. Gene transfer to "stabilize" the "vulnerable" atherosclerotic plaque may prevent plaque rupture and subsequent thrombosis. Possible strategies include overexpressing TIMPs and blocking the action of proinflammatory molecules such as the transcription factor NF-B. 92 Further progress in this area awaits the development of methods to identify vulnerable plaques and the establishment of animal models of plaque rupture.
Angiogenic Gene Therapy
This is an option for severe occlusive atherosclerotic arterial disease refractory to medical therapy and not amenable to mechanical revascularization. Direct administration of angiogenic proteins has several disadvantages, including cost, need for repeated or prolonged administration of protein, and systemic effects. Gene transfer of angiogenic factors is a viable alternative therapy. Vascular endothelial growth factor (VEGF) is an EC mitogen in vitro and an angiogenic growth factor in vivo. 93 In addition, it may have qualitative effects on endothelial function, 94 including stimulation of NO production. 95 In the rabbit ischemic hindlimb model, augmented collateral perfusion occurred after delivery of plasmid DNA encoding VEGF. 96 A trial with human subjects is studying the efficacy of such a method for patients with critical peripheral arterial disease. 97 A plasmid encoding VEGF is delivered to the vasculature proximal to the site of narrowing with use of a hydrogel balloon catheter. Preliminary results seem encouraging, at least in 1 patient. 98 An alternate strategy is intramuscular delivery of VEGF gene in patients with severe diffuse peripheral arterial disease in whom conventional treatment has failed and intravascular catheter-based gene delivery is not possible. Skeletal muscle is able to take up and express naked plasmid DNA. With this method of delivery, augmented collateral development and tissue perfusion were demonstrated in the rabbit model of hindlimb ischemia. 99 Results using such a strategy in 10 patients with severe peripheral arterial disease (7 with nonhealing ulcers/digit gangrene, 3 with rest pain) have been published recently. 100 Clinical status was improved in 8 patients, unchanged in 1, and worse in 1 after 2 to 6 months of follow-up. An increase in the ankle-brachial index, improved flow by magnetic resonance imaging, and angiographic evidence of angiogenesis were noted in several patients.
Successful angiogenic gene therapy for myocardial ischemia has been demonstrated in a porcine model of ameroid constrictor-induced coronary occlusion. 101 Intracoronary delivery of a recombinant adenovirus expressing human fibroblast growth factor (FGF)-5 resulted in marked improvement in myocardial function, blood flow, and increased capillary density. Clinical trials with human subjects involving the adenoviral-mediated expression of FGF-4 to stimulate angiogenesis in ischemic myocardium are under way.
Arterial Restenosis
To develop effective molecular therapies for restenosis, it is important to understand its biology. During the past several years, our understanding of the pathogenesis of restenosis has changed considerably. 102 The concept that luminal loss in restenosis results simply from an increase in intimal mass is no longer valid. Although SMC proliferation is possibly the main mechanism for restenosis after stenting, factors such as thrombosis, platelet activation, vasoconstriction, leukocyte adhesion, matrix elaboration, and remodeling are important pathogenetic mechanisms in other settings. 103 Vascular remodeling may be a major determinant of whether restenosis will occur, and its importance has been highlighted in several animal models 104, 105 and in humans. 29 Therefore, gene therapy approaches to limit restenosis need to be targeted not only at cell proliferation but also at other pathogenetic factors. The various gene transfer strategies that have been used experimentally to limit neointimal formation and restenosis are discussed below.
Antiproliferative Strategies
Gene therapy may be used to decrease cell number in the vascular wall by inducing either cytotoxicity or cytostasis (Table 4) . With mathematical modeling of cell proliferation, a significant and clinically relevant inhibition of neointima formation is predicted at cell transduction rates as low as 10%. 116 However, this modeling does not take into account the contribution of SMC migration to neointima formation and the "bystander" phenomenon thought to occur after HSV-tk gene transfer. The question whether gene transfer for antiproliferative effects is better than drugs such as paclitaxel (Taxol) or plicamycin (Mithramycin) or radiation needs to be considered. With systemically administered antiproliferative medications, the potential for serious side effects is considerable. Similarly, with the use of arterial radiation, the possibility of long-term vascular damage needs to be considered.
Inhibition of SMC Migration
SMC migration and matrix elaboration are important in the pathogenesis of restenosis. 117 Migration of SMCs is mediated partly through the action of metalloproteinases. 118 Local overexpression of a TIMP-1 in injured carotid arteries of rats produced a significant decrease in neointimal hyperplasia. 5 Overexpression of proteins such as eNOS or natriuretic peptides, which increase vascular wall cGMP, may also inhibit SMC migration. 119, 120 Inhibition of Thrombosis Thrombin is important in the vascular response to injury and is an attractive target for pharmacological inhibition in 106 Rat carotid 107 Femoral artery of cholesterol-fed rabbits 108, 109 Requires systemic administration of ganciclovir. This is converted into triphosphorylated metabolite that incorporates into cellular DNA, resulting in chain termination and cytotoxic effect. Apoptosis may also result. Transfer of this metabolite to surrounding cells produces a "bystander" phenomenon Rb Rat carotid and porcine iliac 110 Phosphorylation of Rb is required for cell cycle progression 111 ; expression of nonphosphorylatable analogue of Rb produces cytostatic effect on SMCs p21 protein Rat carotid 112 and porcine iliac 113 p21 inhibits cyclin-dependent kinases required for initiation of S phase H-ras (DN) Rat carotid 114 H-ras is a protooncogene that is a key intracellular transducer of G protein-and tyrosine kinase-linked mitogenic signals CD Rabbit femoral 115 CD gene product is capable of metabolizing the prodrug 5-fluorocytosine to the potent antimetabolite 5-fluorouracil, which inhibits DNA and RNA synthesis and produces a cytostatic effect HSK-tv indicates herpes simplex virus-thymidine kinase; Rb, retinoblastoma gene product; DN, dominant-negative; and CD, cytosine deaminase.
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vivo. 121 Adenoviral-mediated gene transfer of recombinant hirudin, a specific inhibitor of thrombin, decreased neointima formation in the rat carotid artery injury model. 89 In a porcine carotid artery injury model, adenoviral-mediated transfer of the cyclooxygenase gene augmented prostacyclin synthesis and was associated with inhibition of thrombosis. 90 Neointimal formation was not studied in this model, but such an approach may be useful in limiting restenosis.
Acceleration of Endothelialization
Studies in the rat carotid artery model of arterial balloon injury have established an inverse relationship between endothelial integrity and SMC proliferation. 122 Direct application of VEGF to the denuded surface of the rat carotid artery accelerates endothelialization and decreases intimal proliferation. 123 Catheter-mediated gene transfer of a plasmid encoding VEGF to the balloon-injured site of a rabbit femoral artery led to accelerated re-endothelialization at local and remote sites, leading to inhibition of neointimal thickening, reduction of thrombogenicity, and restoration of endothelium-dependent relaxations. 124 A trial with human subjects is under way to test this strategy in peripheral artery angioplasty. 125 However, several aspects of VEGF biology need to be considered as trials with human subjects begin. Upregulation of VEGF has been demonstrated in medial SMCs after balloon injury, 126 which raises the question of the added effectiveness of recombinant VEGF in this situation. VEGF may have mitogenic effects on SMC 127 and thus could exacerbate neointimal formation. 128 Also, VEGF may induce plaque neovascularization in atherosclerotic arteries, with possible deleterious effects.
Pleiotropic Effector Molecules
Because of the more complex vascular lesions in humans, with involvement of several pathogenetic mechanisms that include inflammation and platelet-fibrin thrombus deposition, 117, 129 a "cocktail approach" may be necessary to affect multiple mechanisms. Thus, a mixture of different adenoviral vectors or an adenoviral gene that encodes 2 or more gene products may prove successful. Alternatively, agents with pleiotropic actions are more likely to be effective in limiting neointimal formation than those that act on a single pathogenetic mechanism. 130 Two such molecules are NO and C-type natriuretic peptide (CNP), both of which increase cGMP in the arterial wall. NO is important in the regulation of vascular tone and the prevention of thrombosis. NO donors inhibit SMC proliferation, 131 migration, 120 and matrix production, 132, 133 and platelet 134 and monocyte 135 adhesion. These factors are important in determining neointimal formation, particularly after balloon angioplasty or stenting. Increasing local NO production therefore may uniquely inhibit formation of neointima in vascular disease states. Also, because NO has a role in vascular remodeling, 136 increased NO generation may favor positive remodeling in balloon-injured arteries. 6 Thus, localized eNOS delivery conceptually has several advantages over other forms of gene therapy to limit restenosis. eNOS gene transfer to the injured carotid artery of rats led to a reduction in neointima. 137 Retroviral-mediated gene transfer of the inducible isoform of NOS has also been demonstrated to inhibit myointimal hyperplasia in an ex vivo organ culture model of arterial balloon injury. 138 However, as mentioned above, the effects of NO may depend on the redox state of the vessel wall. In states of excessive oxidant stress such as atherosclerosis or vascular injury, increased NO generation may lead to formation of damaging free radical oxidant species such as peroxynitrite.
CNP is a member of the natriuretic peptide family with vasorelaxing, antimitogenic, and anti-smooth muscle migratory properties. 139 Most of the actions are mediated by the cGMP pathway. Adenoviral-mediated gene transfer of CNP caused a marked decrease of neointimal formation in the rat carotid artery injury model. 140 Because the antiproliferative effects of the vector on SMC in vitro were modest, it is likely that neointimal formation in vivo is limited by several different mechanisms. 140 
Vein Graft Disease
Occlusion of vein grafts is a major limitation to the long-term treatment of occlusive arterial disease. Mann and coworkers 141 demonstrated that inhibition of cell proliferation using antisense technology prevents accelerated atherosclerosis and neointimal formation in jugular vein bypass grafts of cholesterol-fed rabbits. The treated grafts develop medial hypertrophy as an adaptation to increased hemodynamic stress, are resistant to diet-induced atherosclerosis, and have preserved endothelial function. 141, 142 On the basis of these findings, a multicenter trial of intraoperative ex vivo delivery of E2F decoy oligonucleotides to vein grafts in humans to decrease the incidence of graft disease and failures has begun. 20 E2F is a transcription factor that mediates coordinated induction of cell cycle regulatory genes. 143 An alternate strategy of enhancing endothelial function and antithrombotic properties of vein grafts is to increase NO production by expression of recombinant eNOS. Adenoviral-mediated eNOS gene transfer ex vivo to saphenous vein grafts in humans resulted in enhanced relaxations to calcium ionophore and increased nitrite production by treated vein grafts. 19 Such a strategy may decrease the incidence of acute graft occlusion and perhaps allow favorable remodeling.
Systemic and Pulmonary Hypertension
Although hypertension is a polygenic disease, certain key mediators may have significant roles that could be modified by gene transfer. Gene therapy may allow chronic hypertension control, obviating daily lifelong drug therapy. Direct intravenous delivery of plasmid DNA encoding vasodilator proteins has been tested in the spontaneously hypertensive rat (SHR). Plasmid DNA encoding human tissue kallikrein decreased blood pressure for 6 weeks, with a peak decrease of 46 mm Hg. 144 Similar delivery of the atrial natriuretic peptide gene led to reduction in blood pressure after 1 week; the effect lasted up to 7 weeks and was accompanied by diuresis and natriuresis. 145 A similar prolonged decrease in blood pressure was obtained by intravenous delivery of a plasmid encoding eNOS. 146 A novel method of increasing vascular NO production was adopted by Cuevas and coworkers, 147 who observed decreased endothelial basic FGF content in the endothelium of the SHR. Intravenous delivery of a plasmid encoding basic FGF led to increased eNOS expression in the endothelium and attenuated responses to vasoconstrictors.
Primary pulmonary hypertension is a disorder that can be rapidly fatal and for which there is no effective therapy. The expression of eNOS in the pulmonary vasculature of patients with primary pulmonary hypertension is markedly diminished. 148 A novel therapeutic approach to this condition may be to increase eNOS activity in the lungs of patients by gene transfer techniques. Adenoviral-mediated expression of human recombinant eNOS in rat lungs has been shown to attenuate hypoxic vasoconstriction. 36 Recombinant adenovirus was delivered by aerosolization and localized in part to the adventitia of the pulmonary arteries.
Cerebrovascular Disease
Vasospasm is a major cause of mortality and morbidity after subarachnoid hemorrhage. Expression of transgenes such as eNOS in the cerebral vessels may result in vasodilatation and ameliorate vasospasm in such a situation. 37, 149 In a canine model of subarachnoid hemorrhage, intracisternal injection of recombinant adenovirus encoding a reporter gene resulted in gene transfer to the cerebral blood vessels and overlying meninges even in the presence of cisternal blood. 150 Although adenoviral vectors allow only transient expression of transgenes, this may be advantageous in the setting of subarachnoid hemorrhage because spasm typically occurs within 7 to 10 days after the hemorrhage, at a time when transgene expression should still be present.
Summary
Several important insights have been gained after nearly a decade of investigation in vascular gene transfer. In animal models, vascular gene transfer has been used successfully to alter neointimal formation and vasomotor reactivity and to stimulate angiogenesis. However, the shortcomings of such an approach for treating vascular disorders in humans have become apparent. Effects of gene transfer in animal models may not be applicable to diseased human arteries, and more representative animal models need to be established. Currently available vectors have several deficiencies such as transient expression, generation of an immune-inflammatory response, lack of tissue specificity, and unregulated expression. Better percutaneous catheter-based delivery systems need to be developed. Safety and cost-effectiveness issues also need to be considered.
Despite these imperfections, gene therapy for vascular diseases in humans has already begun. This has occurred because of certain unique scenarios rather than the maturation of the field. Gene therapy trials with human subjects to stimulate angiogenesis in ischemic skeletal or cardiac muscle are an example. The first trial involved plasmid-mediated VEGF delivery to stimulate angiogenesis in critically ischemic limbs. 97 Factors such as lack of effective alternative therapy in patients with severe symptomatic peripheral arterial disease, upregulation of VEGF receptors in the setting of ischemia (increasing the chances of obtaining biological effects despite the low efficiency of gene transfer with plasmid-mediated delivery), and presumed endothelial specificity of VEGF receptors led to the approval of a trial with human subjects. A separate arm of this protocol tested the direct administration of naked VEGF DNA into skeletal muscle. 100 This was feasible because skeletal muscle takes up and expresses naked DNA relatively efficiently. Trials of gene transfer are underway to stimulate angiogenesis in chronic severe coronary artery disease for which conventional medical and surgical therapeutic options were exhausted. The stimulus for such trials is the lack of effective therapeutic options in the setting of disabling symptoms, rather than a refinement of gene transfer techniques. More such trials are likely to get under way in the setting of severe vascular disease. In such scenarios, the risk of therapeutic uncertainty and vector imperfections (present with the current first-or second-generation adenoviral vectors) may have to be accepted.
Better understanding of vascular pathobiology, continuing basic science research aimed at refining vectors and delivery systems, and insights from the early trials with human subjects are critical for a broader use of vascular gene transfer. With such developments and close cooperation between clinicians and basic scientists, vascular gene transfer is likely to emerge as an important therapeutic modality for vascular disorders.
